The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian, colorectal, prostate, glioblastoma and endometrial cancers. PI3K signaling plays an important role in cancer cell survival, angiogenesis and metastasis, making it a promising therapeutic target. There are several ongoing and completed clinical trials involving PI3K inhibitors (pan, isoform-specific and dual PI3K/mTOR) with the goal to find efficient PI3K inhibitors that could overcome resistance to current therapies. This review focuses on the current landscape of various PI3K inhibitors either as monotherapy or in combination therapies and the treatment outcomes involved in various phases of clinical trials in different cancer types. There is a discussion of the drug-related toxicities, challenges associated with these PI3K inhibitors and the adverse events leading to treatment failure. In addition, novel PI3K drugs that have potential to be translated in the clinic are highlighted.
The phospatidylinositol-3 kinase (pan class="Gene">PI3K) pathway is a crucial intracellular signaling pathway which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian, colorectal, prostate, glioblastoma and endometrial cancers. PI3K signaling plays an important role in cancer cell survival, angiogenesis and metastasis, making it a promising therapeutic target. There are several ongoing and completed clinical trials involving PI3K inhibitors (pan, isoform-specific and dual PI3K/mTOR) with the goal to find efficient PI3K inhibitors that could overcome resistance to current therapies. This review focuses on the current landscape of various PI3K inhibitors either as monotherapy or in combination therapies and the treatment outcomes involved in various phases of clinical trials in different cancer types. There is a discussion of the drug-related toxicities, challenges associated with these PI3K inhibitors and the adverse events leading to treatment failure. In addition, novel PI3K drugs that have potential to be translated in the clinic are highlighted.
Authors: Dejan Juric; Johann S de Bono; Patricia M LoRusso; John Nemunaitis; Elisabeth I Heath; Eunice L Kwak; Teresa Macarulla Mercadé; Elena Geuna; Maria Jose de Miguel-Luken; Chirag Patel; Keisuke Kuida; Serap Sankoh; Eric H Westin; Fabian Zohren; Yaping Shou; Josep Tabernero Journal: Clin Cancer Res Date: 2017-05-10 Impact factor: 12.531
Authors: A K Gopal; M A Fanale; C H Moskowitz; A R Shustov; S Mitra; W Ye; A Younes; A J Moskowitz Journal: Ann Oncol Date: 2017-05-01 Impact factor: 32.976
Authors: W Yuan; E Stawiski; V Janakiraman; E Chan; S Durinck; K A Edgar; N M Kljavin; C S Rivers; F Gnad; M Roose-Girma; P M Haverty; G Fedorowicz; S Heldens; R H Soriano; Z Zhang; J J Wallin; L Johnson; M Merchant; Z Modrusan; H M Stern; S Seshagiri Journal: Oncogene Date: 2012-02-27 Impact factor: 9.867
Authors: Benjamin D Hopkins; Chantal Pauli; Xing Du; Diana G Wang; Xiang Li; David Wu; Solomon C Amadiume; Marcus D Goncalves; Cindy Hodakoski; Mark R Lundquist; Rohan Bareja; Yan Ma; Emily M Harris; Andrea Sboner; Himisha Beltran; Mark A Rubin; Siddhartha Mukherjee; Lewis C Cantley Journal: Nature Date: 2018-07-04 Impact factor: 49.962
Authors: Daniel J de Klerk; Mark J de Keijzer; Lionel M Dias; Jordi Heemskerk; Lianne R de Haan; Tony G Kleijn; Leonardo P Franchi; Michal Heger Journal: Methods Mol Biol Date: 2022
Authors: Flávia Melo Cunha de Pinho Pessoa; Caio Bezerra Machado; Emerson Lucena da Silva; Laudreísa da Costa Pantoja; Rodrigo Monteiro Ribeiro; Maria Elisabete Amaral de Moraes; Manoel Odorico de Moraes Filho; Raquel Carvalho Montenegro; André Salim Khayat; Caroline Aquino Moreira-Nunes Journal: Int J Mol Sci Date: 2022-03-30 Impact factor: 5.923
Authors: Selinde S Wind; Manon A A Jansen; Melanie Rijsbergen; Michiel J van Esdonk; Dimitrios Ziagkos; Wing C Cheng; Tessa Niemeyer-van der Kolk; John Korsten; Agnieszka Gruszka; Debora Schmitz-Rohmer; David Bonnel; Raphael Legouffe; Florian Barré; Marcel W Bekkenk; Ellen R M de Haas; Koen D Quint; Melanie Rolli; Henk Johan Streefkerk; Jacobus Burggraaf; Maarten H Vermeer; Robert Rissmann Journal: Cancers (Basel) Date: 2022-03-15 Impact factor: 6.639